Yuanlin Wu - Publications

A Critical Review of Cytochrome P450 Enzyme Inhibition by Herbal Phytochemicals: Implications for Drug Interaction Prediction and Herbal Safety.

Journal: Phytotherapy research : PTR

Published: December 18, 2025

Investigation and analysis of the etiology of suspected occupational asthma caused by toluene diisocyanate

Journal: Zhonghua lao dong wei sheng zhi ye bing za zhi = Zhonghua laodong weisheng zhiyebing zazhi = Chinese journal of industrial hygiene and occupational diseases

Published: July 01, 2025

Unveiling unexpected adverse events: post-marketing safety surveillance of gilteritinib and midostaurin from the FDA Adverse Event Reporting database.

Journal: Therapeutic advances in drug safety

Published: June 11, 2024

First-Line Camrelizumab Plus Rivoceranib in Advanced Hepatocellular Carcinoma: A China-Based Cost-Effectiveness Analysis.

Journal: Clinical Medicine Insights. Oncology

Published: May 15, 2024

Cost-effectiveness of nivolumab plus gemcitabine-cisplatin as first-line treatment for advanced urothelial carcinoma in China and the United States.

Journal: Frontiers in immunology

Published: April 30, 2024

Cholinesterase inhibitors-associated torsade de pointes/QT prolongation: a real-world pharmacovigilance study.

Journal: Frontiers in pharmacology

Published: November 24, 2023

Disproportionality Analysis of Nusinersen in the Food and Drug Administration Adverse Event Reporting System: A Real-World Postmarketing Pharmacovigilance Assessment.

Journal: Pediatric neurology

Published: October 09, 2023

Drug-induced interstitial lung disease: a real-world pharmacovigilance study of the FDA Adverse Event Reporting System from 2004 to 2021.

Journal: Therapeutic advances in drug safety

Published: July 07, 2023

Cost-effectiveness of serplulimab as first-line therapy for extensive-stage small cell lung cancer in China.

Journal: Frontiers in immunology

Published: May 18, 2023

Opportunities and challenges of pharmacovigilance in special populations: a narrative review of the literature.

Journal: Therapeutic advances in drug safety

Published: April 28, 2023

Insights into Regulatory Factors in Megakaryocyte Development and Function: Basic Mechanisms and Potential Targets.

Journal: Frontiers in bioscience (Landmark edition)

Published: August 12, 2022

Post-marketing safety of immunomodulatory drugs in multiple myeloma: A pharmacovigilance investigation based on the FDA adverse event reporting system.

Journal: Frontiers in pharmacology

Published: July 08, 2022